JP2012500245A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012500245A5 JP2012500245A5 JP2011523405A JP2011523405A JP2012500245A5 JP 2012500245 A5 JP2012500245 A5 JP 2012500245A5 JP 2011523405 A JP2011523405 A JP 2011523405A JP 2011523405 A JP2011523405 A JP 2011523405A JP 2012500245 A5 JP2012500245 A5 JP 2012500245A5
- Authority
- JP
- Japan
- Prior art keywords
- formula
- pharmaceutically acceptable
- hydromethanesulfonate
- hydromaleate
- hydrofumarate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US9001808P | 2008-08-19 | 2008-08-19 | |
| US61/090,018 | 2008-08-19 | ||
| PCT/EP2009/060592 WO2010020602A1 (en) | 2008-08-19 | 2009-08-17 | Dabigatran for percutaneous interventional cardiac catheterisation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012500245A JP2012500245A (ja) | 2012-01-05 |
| JP2012500245A5 true JP2012500245A5 (https=) | 2012-10-04 |
Family
ID=41258283
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011523405A Pending JP2012500245A (ja) | 2008-08-19 | 2009-08-17 | 経皮的インターベンション心臓カテーテル法のためのダビガトラン |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20110301201A1 (https=) |
| EP (1) | EP2328580A1 (https=) |
| JP (1) | JP2012500245A (https=) |
| KR (1) | KR20110044230A (https=) |
| CN (1) | CN102123707A (https=) |
| AR (1) | AR073077A1 (https=) |
| AU (1) | AU2009284217A1 (https=) |
| BR (1) | BRPI0917507A2 (https=) |
| CA (1) | CA2734794A1 (https=) |
| CL (1) | CL2011000361A1 (https=) |
| CO (1) | CO6290686A2 (https=) |
| EA (1) | EA201100358A1 (https=) |
| EC (1) | ECSP11010825A (https=) |
| IL (1) | IL210005A0 (https=) |
| MA (1) | MA32563B1 (https=) |
| MX (1) | MX2011001612A (https=) |
| NZ (1) | NZ591108A (https=) |
| TW (1) | TW201022235A (https=) |
| WO (1) | WO2010020602A1 (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2009315729A1 (en) | 2008-11-11 | 2010-05-20 | Boehringer Ingelheim International Gmbh | Method for treating or preventing thrombosis using dabigatran etexilate or a salt thereof with improved safety profile over conventional warfarin therapy |
| SI2542224T1 (sl) * | 2010-03-01 | 2014-10-30 | Ratiopharm Gmbh | Oralni farmacevtski sestavek, ki vsebuje dabigatran eteksilat |
| CN102918034B (zh) | 2010-03-30 | 2015-06-03 | 维颂公司 | 多取代芳族化合物作为凝血酶的抑制剂 |
| CN102391250B (zh) * | 2011-08-29 | 2013-06-19 | 石药集团欧意药业有限公司 | 一种达比加群酯化合物、制备方法及其药物组合物 |
| CN102558153A (zh) * | 2012-02-08 | 2012-07-11 | 北京阜康仁生物制药科技有限公司 | 达比加群酯的新药用盐及其制备方法 |
| CN103420985B (zh) * | 2012-05-24 | 2015-09-23 | 天津药物研究院 | 作为前药的达比加群酯衍生物及其制备方法和用途 |
| CN103420994B (zh) * | 2012-05-24 | 2016-04-06 | 天津药物研究院 | 作为前药的达比加群酯衍生物及其制备方法和用途 |
| CN103420982B (zh) * | 2012-05-24 | 2015-07-08 | 天津药物研究院 | 达比加群酯衍生物及其制备方法和用途 |
| CN103420984B (zh) * | 2012-05-24 | 2015-07-08 | 天津药物研究院 | 作为前药的达比加群酯衍生物及其制备方法和用途 |
| CN103524559B (zh) * | 2012-07-05 | 2016-09-28 | 西藏海思科药业集团股份有限公司 | 多取代4-甲氨基苯甲脒的酯衍生物及其制备方法和用途 |
| CN103539779B (zh) * | 2012-07-13 | 2016-12-21 | 四川海思科制药有限公司 | 一种达比加群酯的羟基取代苯磺酸盐及其制备方法和用途 |
| EP2900652A2 (en) * | 2012-09-28 | 2015-08-05 | Ranbaxy Laboratories Limited | Process for the preparation of dabigatran etexilate or pharmaceutically acceptable salt thereof |
| US9399616B2 (en) * | 2012-10-22 | 2016-07-26 | Boehringer Ingelheim International Gmbh | Process for the manufacture of 4-aminobenzoamidine dihydrochloride |
| ES2791749T3 (es) | 2013-03-15 | 2020-11-05 | Verseon Corp | Halogenopirazoles como inhibidores de la trombina |
| LT2968297T (lt) | 2013-03-15 | 2019-01-10 | Verseon Corporation | Multipakeistieji aromatiniai junginiai kaip serino proteazės inhibitoriai |
| CN106687445A (zh) | 2014-09-17 | 2017-05-17 | 维颂公司 | 作为丝氨酸蛋白酶抑制剂的吡唑基取代的吡啶酮化合物 |
| RU2017131562A (ru) | 2015-02-27 | 2019-03-27 | Версеон Корпорейшн | Замещенные пиразольные соединения как ингибиторы сериновых протеаз |
| WO2020014669A1 (en) | 2018-07-13 | 2020-01-16 | Verseon Corporation | Thrombin inhibitors, formulations, and uses thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2476054C (en) * | 2002-03-07 | 2011-11-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pharmaceutical composition for the oral administration of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino)-methyl}-1-methyl-1h-benzimidazol-5-carbonyl)-pyridin-2-yl-amino)-propionic acid ethyl ester and the salts thereof |
| WO2006045756A1 (en) * | 2004-10-25 | 2006-05-04 | Boehringer Ingelheim International Gmbh | Use of dipyridamole in combination with antithrombotics for treatment and prevention of thromboembolic diseases |
| EP2043691A1 (en) * | 2006-07-17 | 2009-04-08 | Boehringer Ingelheim International GmbH | New paediatric indications for direct thrombin inhibitors |
| MX2009000602A (es) * | 2006-07-17 | 2009-01-28 | Boehringer Ingelheim Int | Nuevas indicaciones para los inhibidores directos de la trombina en el campo cardiovascular. |
| US20100087488A1 (en) * | 2006-10-10 | 2010-04-08 | Boehringer Ingelheim International Gmgh | Physiologically Acceptable Salts of 3-[(2--1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester |
-
2009
- 2009-08-17 NZ NZ591108A patent/NZ591108A/xx not_active IP Right Cessation
- 2009-08-17 EP EP09781886A patent/EP2328580A1/en not_active Withdrawn
- 2009-08-17 BR BRPI0917507A patent/BRPI0917507A2/pt not_active IP Right Cessation
- 2009-08-17 EA EA201100358A patent/EA201100358A1/ru unknown
- 2009-08-17 WO PCT/EP2009/060592 patent/WO2010020602A1/en not_active Ceased
- 2009-08-17 CN CN2009801318235A patent/CN102123707A/zh active Pending
- 2009-08-17 US US13/058,920 patent/US20110301201A1/en not_active Abandoned
- 2009-08-17 MX MX2011001612A patent/MX2011001612A/es not_active Application Discontinuation
- 2009-08-17 KR KR1020117003645A patent/KR20110044230A/ko not_active Withdrawn
- 2009-08-17 CA CA2734794A patent/CA2734794A1/en not_active Abandoned
- 2009-08-17 AU AU2009284217A patent/AU2009284217A1/en not_active Abandoned
- 2009-08-17 JP JP2011523405A patent/JP2012500245A/ja active Pending
- 2009-08-18 TW TW098127736A patent/TW201022235A/zh unknown
- 2009-08-18 AR ARP090103168A patent/AR073077A1/es unknown
-
2010
- 2010-12-15 IL IL210005A patent/IL210005A0/en unknown
-
2011
- 2011-02-11 EC EC2011010825A patent/ECSP11010825A/es unknown
- 2011-02-15 MA MA33616A patent/MA32563B1/fr unknown
- 2011-02-17 CO CO11018905A patent/CO6290686A2/es not_active Application Discontinuation
- 2011-02-18 CL CL2011000361A patent/CL2011000361A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012500245A5 (https=) | ||
| US9809545B2 (en) | Factor XIa inhibitors | |
| US20210221793A1 (en) | Pyrazole derivatives as sgc stimulators | |
| JP2007537187A5 (https=) | ||
| CA2674436A1 (en) | Amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors | |
| NZ595829A (en) | 8-[4-(1-Aminocyclobutyl)phenyl]-9-phenyl[1,2,4]triazolo[3,4-f]-1,6-naphthyridine derivatives | |
| US10173998B2 (en) | Antifungal compound process | |
| JP2009514837A5 (https=) | ||
| US20080200514A1 (en) | Indications for Direct Thrombin Inhibitors | |
| JP2010515715A5 (https=) | ||
| KR101775304B1 (ko) | 퀴놀론 화합물의 제조 방법 | |
| JP2006523216A5 (https=) | ||
| JP2014520809A5 (https=) | ||
| NZ592508A (en) | Pyrazine compounds as phosphodiesterase 10 inhibitors | |
| JP2014037426A5 (https=) | ||
| JP2009510064A5 (https=) | ||
| JP2010516700A5 (https=) | ||
| CN115315423A (zh) | 取代芳基类化合物 | |
| WO2008009210A8 (fr) | Composés de dihydropyrimidine optiquement purs et leurs utilisations dans la fabrication d'un médicament pour traiter ou prévenir des viroses | |
| EP2765860A1 (en) | Mineralocorticoid receptor antagonists | |
| US20250243228A1 (en) | PHOSPHORUS PRODRUGS OF PYRAZOLO-SUBSTITUTED PYRIMIDINE sGC STIMULATORS | |
| JP2009511450A5 (https=) | ||
| JP2009543844A (ja) | 直接トロンビン阻害剤の新しい小児適応症 | |
| CA2667041A1 (en) | N-(2-hydroxyethyl)-n-methyl-4-(quinolin-8-yl(1-(thiazol-4-ylmethyl)piperidin-4-ylidene)methyl)benzamide, the process of making it as well as its use for the treatment of pain, anxiety and depression | |
| JP2007519703A5 (https=) |